Isomorphic Labs
Alphabet's drug-design lab — AlphaFold, commercialized into an active pharma pipeline.
isomorphiclabs.com ↗Isomorphic is the most credible AI drug-design company in existence — built by the team that won the Nobel Prize for solving the single biggest problem in computational biology. The active partnerships with Eli Lilly and Novartis at multi-billion milestone scale give Isomorphic real commercial validation; the coming first-in-human trials for AI-designed drugs will be the category-defining moment for the whole AI + biology intersection. For AI-for-science founders, Isomorphic is the benchmark for what it takes to do this seriously.
What's going for them.
- 01Built on AlphaFold — the Nobel-Prize-winning protein-structure prediction system from DeepMind — and now running its own in-house drug-design engine that reportedly doubles AlphaFold 3's protein-ligand benchmark performance.
- 02Two active multi-billion pharma partnerships with Eli Lilly and Novartis — total potential milestone payments of $2.9B — validating the AI-drug-design approach at the scale of top-5 pharma R&D budgets.
- 03Preparing to launch clinical trials for AI-designed drugs — a category-defining milestone. If the molecules work in humans, the AI drug-discovery thesis moves from 'promising' to 'proven.'
- 04Demis Hassabis — DeepMind founder, 2024 Nobel laureate in Chemistry for AlphaFold — is still active as CEO. The research leadership depth is unmatched in the category.
- 05The $600M external round (Mar 2025), led by Thrive with GV participation, was Isomorphic's first outside capital — a signal that Alphabet is prepared to let the business operate with real external accountability and strategic flexibility.
What they built
Isomorphic Labs is an AI-driven drug design company, spun out of Alphabet/DeepMind in 2021 to commercialize the protein-structure and molecular-design capabilities that grew out of AlphaFold. The product isn’t a model API — it’s a drug-discovery platform that Isomorphic runs in-house on its own pipeline and with pharma partners. The internal Drug Design Engine, announced in February 2026, reportedly doubles AlphaFold 3’s performance on protein-ligand structure prediction benchmarks, and is now running active target identification across neurology, oncology, and rare diseases.
How they got here
Demis Hassabis founded Isomorphic in late 2021 as a separate Alphabet company, betting that AlphaFold’s protein-structure breakthrough would enable a step-change in how drugs get designed. The first three years were deliberately slow: building the platform, validating on published datasets, and building the team of pharma-experienced scientists that the mostly-ML DeepMind alumni needed. The commercial inflection came in January 2024 with two announced partnerships — Eli Lilly ($45M upfront, up to $1.7B milestones) and Novartis ($37.5M, up to $1.2B milestones) — covering multiple therapeutic targets across small-molecule drug design.
The March 2025 $600M external round, led by Thrive Capital with GV participation, was Isomorphic’s first outside capital. The strategic message was clear: Alphabet believes the company is ready for independent accountability and the capital discipline that comes with outside investors. The February 2026 Drug Design Engine announcement and the imminent launch of first-in-human trials for AI-designed molecules are the two near-term milestones that will define Isomorphic’s next 18 months.
What’s ahead
Three storylines matter. First, clinical trials: Isomorphic has said AI-designed drugs will enter clinical trials in 2026. Even Phase 1 data — safety, pharmacokinetics — will be the first real-world validation of the AI-drug-discovery thesis at this credibility tier. Second, partnership expansion: the Lilly and Novartis deals are structured to expand if the first targets progress; and other top-10 pharma companies are reportedly in active discussion. Third, IPO or spinout: with $600M of external capital raised, Isomorphic is on a path that typically ends in a public listing within 3–5 years. The timing depends on clinical data.
Why it matters
Isomorphic is the company that will decide whether “AI for drug discovery” becomes a real category over the next decade, or remains a frustrating loop of promising research papers. The Nobel Prize gives Hassabis and team an amount of scientific credibility no other AI-bio company has. For founders in vertical AI (healthcare, materials, biotech), the Isomorphic trajectory — deep research, patient commercialization, credentialed partnerships — is the playbook for categories where the stakes are biological, not software.
Founder interview coming soon.
We'll be sitting down with the founders and operators of the companies we profile — on fundraising, product decisions, and what they're building next. If you're part of the Isomorphic Labs team and want to share a perspective, get in touch.
Thinking about fundraising or M&A?
Amafi Advisory works with AI companies on strategic, fundraising, M&A, and technical advisory. Even if you're just exploring.